<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00775255</url>
  </required_header>
  <id_info>
    <org_study_id>CPU-M-025/CLARI-250/05</org_study_id>
    <nct_id>NCT00775255</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Clarithromycin 250 mg/5 mL Powder for Oral Suspension Under Fasting Conditions</brief_title>
  <official_title>An Open Label, Balanced, Randomised, Two-Treatment, Two-Period, Two-Sequence, Single-Dose, Crossover, Bioavailability Study on Clarithromycin Formulations Comparing Clarithromycin 250 mg/5 mL Powder for Oral Suspension of Ranbaxy Laboratories With Biaxin速 Granules 250 mg/5 mL Oral Suspension in Healthy, Adult, Human, Male Subjects Under Fasting Conditions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ranbaxy Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ranbaxy Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the single-dose oral bioavailability of clarithromycin 250-mg/5 mL powder for oral&#xD;
      suspension of Ranbaxy Laboratories with that of Abbott Laboratories (Biaxin速) following&#xD;
      administration of a 250 mg/5 mL dose in healthy, adult, human, male subjects under fasting&#xD;
      conditions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study was conducted as an open label, balanced, randomised, two-treatment, two-period,&#xD;
      two-sequence, single-dose, crossover, bioavailability study on clarithromycin formulations&#xD;
      comparing clarithromycin 250 mg/5 mL powder for oral suspension of Ranbaxy Laboratories with&#xD;
      Biaxin速 granules 250 mg/5 mL oral suspension (containing clarithromycin 250 mg/5mL) of Abbott&#xD;
      Laboratories in healthy, adult, human, male subjects under fasting conditions.&#xD;
&#xD;
      A single oral dose of clarithromycin 250-mg/5 mL was administered during each period of the&#xD;
      study under supervision of a trained Medical Officer.&#xD;
&#xD;
      During the course of the study safety parameters assessed were vital signs, twelve-lead ECG,&#xD;
      clinical examination, medical history, clinical laboratory safety tests (hematology,&#xD;
      biochemical parameters and urine analysis) at base line and hematology and biochemical&#xD;
      parameters at 24 hours post dose of the last period of the study. Twelve-lead ECG was&#xD;
      recorded at 4 and 8 hours post-dose in each period.&#xD;
&#xD;
      A Validated analytical method was used for the analysis of Clarithromycin in human plasma.&#xD;
      Pharmacokinetic and statistical analysis was performed to conclude the bioequivalence.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">December 2005</completion_date>
  <primary_completion_date type="Actual">September 2005</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence</measure>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>clarithromycin 250 mg/5 mL powder for oral suspension of Ranbaxy Laboratories</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Biaxin速 granules 250 mg/5 mL oral suspension</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clarithromycin 250 mg/5 mL powder for oral suspension</intervention_name>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Be in the age range of 18-45 years.&#xD;
&#xD;
          2. Be neither overweight nor underweight for his/her height as per the Life Insurance&#xD;
             Corporation of India height/weight chart for non-medical cases.&#xD;
&#xD;
          3. Have voluntarily given written informed consent to participate in this study.&#xD;
&#xD;
          4. Be of normal health as determined by medical history and physical examination of the&#xD;
             subjects performed within 14 days prior to the commencement of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of allergy to clarithromycin, erythromycin and related macrolides.&#xD;
&#xD;
          2. History of severe diarrhoea within 2 weeks preceding Day 1 of this study.&#xD;
&#xD;
          3. Any evidence of organ dysfunction or any clinically significant deviation from the&#xD;
             normal, in physical or clinical determinations.&#xD;
&#xD;
          4. Presence of disease markers of HIV 1 or 2, Hepatitis B or C viruses or syphilis&#xD;
             infection.&#xD;
&#xD;
          5. Presence of values which were significantly different from normal reference ranges (as&#xD;
             defined in Appendix 5) and/or judged clinically significant for haemoglobin, total&#xD;
             white blood cells count, differential WBC count or platelet count.&#xD;
&#xD;
          6. Positive for urinary screen testing of drugs of abuse (opiates or cannabinoids)&#xD;
&#xD;
          7. Presence of values which were significantly different from normal reference ranges (as&#xD;
             defined in Appendix 5) and/or judged clinically significant for serum creatinine,&#xD;
             blood urea nitrogen, serum aspartate aminotransferase (AST), serum alanine&#xD;
             aminotransferase (ALT), serum alkaline phosphatase, serum bilirubin, plasma glucose or&#xD;
             serum cholesterol.&#xD;
&#xD;
          8. Clinically abnormal chemical and microscopic examination of urine defined as presence&#xD;
             of RBC, WBC (&gt;4/HPF), glucose (positive) or protein (positive).&#xD;
&#xD;
          9. Clinically abnormal ECG or Chest X-ray.&#xD;
&#xD;
         10. QTc interval beyond normal limits.&#xD;
&#xD;
         11. History of serious gastrointestinal, hepatic, renal, cardiovascular, pulmonary,&#xD;
             neurological or haematological disease, diabetes or glaucoma.&#xD;
&#xD;
         12. History of any psychiatric illness which might have impair the ability to provide&#xD;
             written informed consent.&#xD;
&#xD;
         13. Regular smokers who smoke more than 10 cigarettes daily or have difficulty abstaining&#xD;
             from smoking for the duration of each study period.&#xD;
&#xD;
         14. History of drug dependence or excessive alcohol intake on a habitual basis of more&#xD;
             than 2 units of alcoholic beverages per day (1 unit equivalent to half pint of beer or&#xD;
             1 glass of wine or 1 measure of spirit) or have difficulty in abstaining for the&#xD;
             duration of each study period.&#xD;
&#xD;
         15. Use of any enzyme modifying drugs within 30 days prior to Day 1 of this study.&#xD;
&#xD;
         16. Participation in any clinical trial within 12 weeks preceding Day 1 of this study.&#xD;
&#xD;
         17. Subjects who, through completion of this study, would have donated and/or lost more&#xD;
             than 350 mL of blood in the past 3 months.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Gurgaon</city>
        <state>Haryana</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <link>
    <url>http://clinicalstudies.ranbaxy.com</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://dailymed.nlm.nih.gov/dailymed/about.cfm</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://www.fda.gov/opacom/7alerts.html</url>
    <description>Related Info</description>
  </link>
  <verification_date>October 2008</verification_date>
  <study_first_submitted>October 16, 2008</study_first_submitted>
  <study_first_submitted_qc>October 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2008</study_first_posted>
  <last_update_submitted>October 16, 2008</last_update_submitted>
  <last_update_submitted_qc>October 16, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr. Tausif Monif</name_title>
    <organization>Ranbaxy Research Laboratories,</organization>
  </responsible_party>
  <keyword>Bioequiavelnce clarithromycin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clarithromycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

